Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. 1983

A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman

Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtained in 45% of the MP group and 31% of the M group (P less than 0.05). No significant difference in response with regard to clinical stage was noted. Median survival was 36 months in the MP group and 29 months in the M group. Survival was longer in stage I and II myeloma than in the stage III cases, at least in the MP group. The median and 5-yr survival rates in stages I and II were significantly better in the MP than in the M group. Response to therapy was associated with length of survival, median survival being 62 months in responding patients and 20 months in non-responders. The MP and M groups did not differ in this respect.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
April 1977, Harefuah,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
November 2019, The Korean journal of internal medicine,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
September 2015, Blood,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
June 1967, Cancer chemotherapy reports,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
May 1988, Journal of the National Cancer Institute,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
April 1973, Archives of internal medicine,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
November 1983, Lancet (London, England),
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
January 2002, Drugs & aging,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
January 1975, Medical and pediatric oncology,
A Ahre, and M Björkholm, and H Mellstedt, and G Holm, and G Brenning, and L Engstedt, and G Gahrton, and J Hällen, and B Johansson, and S G Johansson, and L Karnström, and A Killander, and R Lerner, and D Lockner, and B Lönnqvist, and B Simonsson, and A M Stalfelt, and B Ternstedt, and B Wadman
December 1986, Giornale di clinica medica,
Copied contents to your clipboard!